SG11201407988UA - Process for improved opioid synthesis - Google Patents

Process for improved opioid synthesis

Info

Publication number
SG11201407988UA
SG11201407988UA SG11201407988UA SG11201407988UA SG11201407988UA SG 11201407988U A SG11201407988U A SG 11201407988UA SG 11201407988U A SG11201407988U A SG 11201407988UA SG 11201407988U A SG11201407988U A SG 11201407988UA SG 11201407988U A SG11201407988U A SG 11201407988UA
Authority
SG
Singapore
Prior art keywords
international
july
compositions
compounds
apis
Prior art date
Application number
SG11201407988UA
Other languages
English (en)
Inventor
Keith Mccarthy
Joshua R Giguere
Stuart James Gebbie
Lonn S Rider
Original Assignee
Rhodes Technologies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhodes Technologies filed Critical Rhodes Technologies
Publication of SG11201407988UA publication Critical patent/SG11201407988UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicinal Preparation (AREA)
SG11201407988UA 2012-07-16 2013-07-15 Process for improved opioid synthesis SG11201407988UA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261672260P 2012-07-16 2012-07-16
US201261741480P 2012-07-19 2012-07-19
US201361762637P 2013-02-08 2013-02-08
PCT/IB2013/001541 WO2014013313A1 (en) 2012-07-16 2013-07-15 Process for improved opioid synthesis

Publications (1)

Publication Number Publication Date
SG11201407988UA true SG11201407988UA (en) 2015-01-29

Family

ID=48916127

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201407988UA SG11201407988UA (en) 2012-07-16 2013-07-15 Process for improved opioid synthesis

Country Status (22)

Country Link
US (3) US10316042B2 (pt)
EP (1) EP2872516B1 (pt)
JP (1) JP6236447B2 (pt)
KR (1) KR101946103B1 (pt)
CN (1) CN104470928B (pt)
AR (1) AR092858A1 (pt)
AU (2) AU2013291725B2 (pt)
BR (1) BR112015000944A2 (pt)
CA (2) CA2974010A1 (pt)
CO (1) CO7180188A2 (pt)
EA (1) EA028092B1 (pt)
ES (1) ES2647949T3 (pt)
HK (1) HK1210170A1 (pt)
IL (1) IL236710B (pt)
IN (1) IN2015DN01165A (pt)
MX (1) MX363610B (pt)
NZ (1) NZ628699A (pt)
PH (1) PH12015500089B1 (pt)
SG (1) SG11201407988UA (pt)
TW (2) TWI643859B (pt)
UA (1) UA117225C2 (pt)
WO (1) WO2014013313A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5923827B2 (ja) * 1981-12-16 1984-06-05 フエザ−安全剃刀株式会社 安全かみそり刃
US20150259355A1 (en) 2012-07-16 2015-09-17 Rhodes Technologies Process for improved opioid synthesis
AU2014298257B2 (en) * 2013-08-02 2016-11-10 Macfarlan Smith Limited Process for the preparation of oxymorphone
KR101868723B1 (ko) 2014-01-15 2018-06-18 로드스 테크놀로지즈 개선된 옥시코돈 합성을 위한 방법
KR101868724B1 (ko) 2014-01-15 2018-06-18 로드스 테크놀로지즈 개선된 옥시모르폰 합성을 위한 방법
US20170342084A1 (en) * 2014-07-09 2017-11-30 Rhodes Technologies Reduction of alpha, beta-unsaturated ketone levels in morphinan derivative compositions
US20160052932A1 (en) 2014-08-25 2016-02-25 Johnson Matthey Public Limited Company Processes for Making Opioids Including 14-Hydroxycodeinone and 14-hydroxymorphinone
US20160340362A1 (en) * 2015-05-20 2016-11-24 Noramco, Inc. Process For The Preparation Of Oxymorphone Freebase
ES2701855T3 (es) 2016-05-31 2019-02-26 Alcaliber Investig Desarrollo E Innovacion Slu Proceso para la obtención de 3,14-diacetiloximorfona a partir de oripavina
US10935314B2 (en) * 2019-03-21 2021-03-02 Evan Prout Heating values of cellulosic waste
CN113493460A (zh) * 2020-03-20 2021-10-12 江苏恩华药业股份有限公司 盐酸羟考酮杂质b的制备方法
IL302416A (en) 2020-11-02 2023-06-01 Rhodes Tech A process for purifying noroxymorphone
US11247999B1 (en) 2021-07-02 2022-02-15 Joseph DeGraw Facile conversion of morphine to normorphine

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2772270A (en) 1954-10-21 1956-11-27 M J Lewenstein 14-hydroxymorphinone and 8, 14-dihydroxydihydromorphinone
US3173876A (en) 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
NL271831A (pt) 1960-11-29
US3276586A (en) 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
NL6714885A (pt) 1967-11-02 1969-05-06
US3541006A (en) 1968-07-03 1970-11-17 Amicon Corp Ultrafiltration process
US3541005A (en) 1969-02-05 1970-11-17 Amicon Corp Continuous ultrafiltration of macromolecular solutions
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4063064A (en) 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4285987A (en) 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4861598A (en) 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
DE3812567A1 (de) 1988-04-15 1989-10-26 Basf Ag Verfahren zur herstellung pharmazeutischer mischungen
US5215758A (en) 1991-09-11 1993-06-01 Euroceltique, S.A. Controlled release matrix suppository for pharmaceuticals
US5273760A (en) 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5286493A (en) 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5472712A (en) 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5324351A (en) 1992-08-13 1994-06-28 Euroceltique Aqueous dispersions of zein and preparation thereof
DK1416842T3 (da) 2001-07-18 2009-03-16 Euro Celtique Sa Farmaceutiske kombinationer af oxycodon og naloxon
US6864370B1 (en) 2003-06-05 2005-03-08 Zhaiwei Lin Process for manufacturing oxycodone
US20050203115A1 (en) * 2004-03-10 2005-09-15 Sancilio Frederick D. Narcotic-NSAID ion pairs
TW201509943A (zh) 2004-03-30 2015-03-16 Euro Celtique Sa 含有小於２５ｐｐｍ１４-羥可待因酮之羥可酮鹽酸鹽之組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝
SK286087B6 (sk) * 2004-08-18 2008-03-05 Zentiva, A. S. Spôsob prípravy oxykodonu
GB0421149D0 (en) 2004-09-23 2004-10-27 Johnson Matthey Plc Preparation of oxycodone
CA2614223A1 (en) 2005-02-24 2006-08-31 Dr Pharma Nova, Llc A registry method and control system for dea schedule ii-v medicines
US8067597B2 (en) 2005-06-16 2011-11-29 Mallinckrodt Llc Synthetic route to 14-hydroxyl opiates through 1-halo-thebaine or analogs
KR100753432B1 (ko) 2005-11-08 2007-08-31 경희대학교 산학협력단 다결정 실리콘 및 그의 결정화 방법
US20070117826A1 (en) 2005-11-23 2007-05-24 Forest Laboratories, Inc. Pharmaceutical formulations comprising ibuprofen, oxycodone, and 14-hydroxycodeinone
US7906647B2 (en) 2006-12-04 2011-03-15 Noramco, Inc. Process for preparing oxycodone having reduced levels of 14-hydroxycodeinone
ATE543823T1 (de) * 2006-12-04 2012-02-15 Noramco Inc Verfahren zur reduzierung von unreinheiten in oxycodonbase
GB0624880D0 (en) 2006-12-14 2007-01-24 Johnson Matthey Plc Improved method for making analgesics
WO2008118654A1 (en) 2007-03-23 2008-10-02 Mallinckrodt Inc. Improved preparation of oxymorphone from oripavine
WO2008130553A1 (en) * 2007-04-16 2008-10-30 Mallinckrodt Inc. Novel opiate reduction utilizing catalytic hydrogen transfer reaction
WO2010140636A1 (ja) 2009-06-03 2010-12-09 高砂香料工業株式会社 不斉水素化触媒
EP2477984B1 (en) * 2009-09-16 2016-08-03 Monash University A method for the n-demethylation of n-methyl heterocycles
EP2377866B1 (en) * 2010-03-23 2014-02-26 Siegfried AG Preparation of low impurity opiates in a continuous flow reactor
AU2011263416B2 (en) * 2010-06-11 2014-04-10 Rhodes Technologies Process for N-dealkylation of tertiary amines
EP2588481B1 (en) * 2010-07-02 2017-11-15 Johnson Matthey Public Limited Company Process for the synthesis and purification of oxycodone
US20120010412A1 (en) 2010-07-08 2012-01-12 Alkermes, Inc. Process for the Synthesis of Substituted Morphinans
JP5780933B2 (ja) 2010-12-01 2015-09-16 高砂香料工業株式会社 光学活性メントールの製造方法
WO2013188418A1 (en) 2012-06-11 2013-12-19 Jianguang Sun Improved method of preparing oxymorphone
US20150259355A1 (en) 2012-07-16 2015-09-17 Rhodes Technologies Process for improved opioid synthesis
CN103113378B (zh) 2013-02-20 2016-04-06 北京华素制药股份有限公司 一种盐酸羟吗啡酮的合成方法
CN103433076B (zh) 2013-09-02 2015-06-24 浙江新和成股份有限公司 一种固载型不对称催化剂及其在不对称氢化反应中的应用
CN106164078A (zh) 2013-12-18 2016-11-23 科迪实验室公司 氧可酮盐酸盐的合成
US10227354B2 (en) 2013-12-18 2019-03-12 Cody Laboratories, Inc. Conversion of oxycodone base to oxycodone hydrochloride
US8846923B1 (en) 2013-12-18 2014-09-30 Cody Laboratories, Inc. Preparation of 14-hydroxycodeinone sulfate
US9062062B1 (en) 2013-12-18 2015-06-23 Cody Laboratories, Inc. Synthesis of oxycodone hydrochloride
KR101868723B1 (ko) 2014-01-15 2018-06-18 로드스 테크놀로지즈 개선된 옥시코돈 합성을 위한 방법
KR101868724B1 (ko) 2014-01-15 2018-06-18 로드스 테크놀로지즈 개선된 옥시모르폰 합성을 위한 방법

Also Published As

Publication number Publication date
US10316042B2 (en) 2019-06-11
EP2872516B1 (en) 2017-08-30
US20230130617A1 (en) 2023-04-27
IL236710A0 (en) 2015-02-26
HK1210170A1 (en) 2016-04-15
US20150315203A1 (en) 2015-11-05
TW201416369A (zh) 2014-05-01
JP6236447B2 (ja) 2017-11-22
AU2013291725A1 (en) 2014-12-18
EP2872516A1 (en) 2015-05-20
IN2015DN01165A (pt) 2015-06-26
PH12015500089A1 (en) 2015-03-02
TWI643859B (zh) 2018-12-11
MX2015000879A (es) 2017-02-14
TWI643860B (zh) 2018-12-11
JP2015524407A (ja) 2015-08-24
TW201641502A (zh) 2016-12-01
US20190367526A1 (en) 2019-12-05
EA201590222A1 (ru) 2015-05-29
WO2014013313A1 (en) 2014-01-23
UA117225C2 (uk) 2018-07-10
BR112015000944A2 (pt) 2019-10-15
KR101946103B1 (ko) 2019-02-08
EA028092B1 (ru) 2017-10-31
CA2879270C (en) 2017-09-05
ES2647949T3 (es) 2017-12-27
NZ628699A (en) 2016-05-27
PH12015500089B1 (en) 2015-03-02
CA2879270A1 (en) 2014-01-23
CN104470928A (zh) 2015-03-25
AR092858A1 (es) 2015-05-06
CN104470928B (zh) 2017-08-11
IL236710B (en) 2018-04-30
CO7180188A2 (es) 2015-02-09
CA2974010A1 (en) 2014-01-23
MX363610B (es) 2019-03-28
AU2013291725B2 (en) 2016-07-28
AU2016204926A1 (en) 2016-07-28
KR20150029752A (ko) 2015-03-18

Similar Documents

Publication Publication Date Title
SG11201407988UA (en) Process for improved opioid synthesis
SG11201907034PA (en) Methods of treating influenza
SG11201804170RA (en) Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
SG11201809499UA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201500005SA (en) Pyrimidine pyrazolyl derivatives
SG11201900633XA (en) Piperidine cxcr7 receptor modulators
SG11201810177VA (en) Pet-imaging immunomodulators
SG11201407200TA (en) Liquid formulation
SG11201810429UA (en) Anti-cd19 antibody formulations
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201408750VA (en) NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS
SG11201909807TA (en) Methods of manufacturing of niraparib
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201402986RA (en) Kinase inhibitors
SG11201406787TA (en) Rnai-based therapies for cardiomyopathies, muscular dystrophies and laminopathies
SG11201909735YA (en) Therapeutic compounds and compositions, and methods of use thereof
SG11201811804QA (en) Oxadiazolopyridine derivates for use as ghrelin o-acyl transferase (goat) inhibitors
SG11201809560QA (en) Enhancer of zeste homolog 2 inhibitors
SG11201407575PA (en) 5-amino[1,4]thiazines as bace 1 inhibitors
SG11201407679PA (en) Manufacture of degarelix
SG11201901689YA (en) Compounds for treating diseases associated with a mitochondrial dysfonction
SG11201805142RA (en) Pharmaceutical compositions comprising phenylaminopyrimidine derivative
SG11201408260RA (en) Process for the production of methylbutinol
SG11201407599SA (en) Oligonucleotide chelate complex-polypeptide compositions and methods
SG11201909906QA (en) Organic compounds